Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

PRECOS Launches PUMA at AACR 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Company launches portfolio of techniques and models of acquired resistance to targeted agents and standards of care used in oncology.

Preclinical Oncology Services Limited (PRECOS) has launched PRECOS Unique Models of Acquired resistance (PUMA) at the AACR annual meeting (Washington DC, April 6th - 10th).

Derived from cell lines and proprietary PDX (Patient-Derived Xenograft) models, PUMA models provide a unique bespoke collection of clinically relevant and validated models of resistance, as well as the techniques and expertise to develop client specific models of acquired resistance to chemotherapeutics and targeted agents.

Such models are a major advancement for pharmaceutical and biotech companies running oncology R&D programmes and will enhance success rates during the critical phase of transitioning from pre-clinical to clinical evaluation of new drug candidates.

The first available examples of PUMA models are in specific lung cancer subsets where PRECOS has previously developed and characterized a focused panel of PDX lung cancer models derived directly from Caucasian patient tumour material - PRECOS’ unique model atlas LION (Lung In ONcology).

By repeatedly challenging relatively homogeneous cell line populations (CTX models) and heterogeneous tumours from PDX models across several passages, PRECOS is able to compare and contrast behaviour such as growth characteristics with gene expression and pathway analysis, response to chemotherapeutics and targeted agents.

It is also possible to assess the effect of varying treatment regimens and dosing strategies including drug holidays or combination therapies.

This allows panels of tumour subset specific models to be built which are able to mimic patients and their responses to treatment regimes in the clinic.

PRECOS is committed to further developing PUMA and is continuing to progress the techniques to provide customized services.

This will enable its clients to build models based on the characteristics of diverse cancer cell types which can offer insights for designing optimal treatment strategies around their pre-clinical candidates prior to product development and clinical trials.

“As oncology R&D progresses, there is an increasingly critical need for more clinically-relevant predictive pre-clinical models in order to overcome the high attrition rates of agents entering clinical trials,” said Dr Martin Page, Scientific Consultant, PRECOS.

Dr Page continued, “All new agents entering phase 1 clinical trials will be tested in cancer patients that have likely become resistant to a range of targeted and chemotherapeutic agents. PUMA is part of our PREdict platform, and offers PRECOS’ clients pre-clinical models that are authentic counterparts of the drug-resistant tumour subsets seen in the clinic, rather than drug-naive models. PRECOS’ latest portfolio offers specialist drug resistant pre-clinical models with responses of higher predictability with outcomes that can be seen during clinical testing.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Latest Advances in PDX Modelling for Oncology Drug Discovery
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.
Friday, September 13, 2013
PRECOS Awarded HTA License and Expands PDX Drug Discovery Models
Company has been awarded license to store and research human tissue samples by the Human Tissue Authority.
Monday, August 27, 2012
PRECOS Appoints Dr Martin Page as Scientific Consultant
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Tuesday, February 21, 2012
PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
Wednesday, March 23, 2011
PRECOS Doubles Capacity and Appoints New Senior Scientific Staff to Accommodate Significant Growth
The company has expanded to accommodate existing and anticipated growth in line with its leadership in oncology drug discovery.
Tuesday, February 15, 2011
Scientific News
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos